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Background:MUC2 polymers form the mucus layer of colon that separates luminal bacteria from the epithelium.
Results: P. gingivalis secrets a protease that cleaves the MUC2 mucin, a cleavage modulated by O-glycosylation.
Conclusion: Bacteria can disrupt theMUC2 polymer via proteolytic cleavage. However,O-glycosylation can inhibit this process.
Significance: Bacteria can dissolve the protective inner mucus layer, potentially triggering colitis.
The colonic epithelial surface is protected by an inner mucus
layer that the commensal microflora cannot penetrate. We pre-
viously demonstrated thatEntamoebahistolytica secretes a pro-
tease capable of dissolving this layer that is required for parasite
penetration. Here, we asked whether there are bacteria that can
secrete similar proteases. We screened bacterial culture super-
natants for such activity using recombinant fragments of the
MUC2 mucin, the major structural component, and the only
gel-formingmucin in the colonic mucus. MUC2 has two central
heavily O-glycosylated mucin domains that are protease-resis-
tant and has cysteine-rich N and C termini responsible for
polymerization. Culture supernatants of Porphyromonas gingi-
valis, a bacterium that secretes proteases responsible for perio-
dontitis, cleaved the MUC2 C-terminal region, whereas the
N-terminal region was unaffected. The active enzyme was iso-
lated and identified as Arg-gingipain B (RgpB). Two cleavage
sites were localized to IR2TT and NR2QA. IR2TT cleavage
will disrupt the MUC2 polymers. Because this site has two
potential O-glycosylation sites, we tested whether recombinant
GalNAc-transferases (GalNAc-Ts) could glycosylate a synthetic
peptide covering the IRTT sequence. Only GalNAc-T3 was able
to glycosylate the second Thr in IRTT, rendering the sequence
resistant to cleavage by RgpB. Furthermore, when GalNAc-T3
was expressed in CHO cells expressing the MUC2 C terminus,
the second threonine was glycosylated, and the protein became
resistant to RgpB cleavage. These findings suggest that bacteria
can produce proteases capable of dissolving the inner protective
mucus layer by specific cleavages in the MUC2 mucin and that
this cleavage can be modulated by site-specificO-glycosylation.
The mucus that covers the epithelium is important for the
protection of surface lining epithelia in the gastrointestinal
tract. Recent studies have shown that there are two mucus lay-
ers in the colon: an outer “loose” layer and an innermucus layer
that is “firmly” attached to the epithelium (1). Goblet cells
secrete theMUC2mucin polymers, which after volume expan-
sion is self-assembled into layered sheets that build the inner
mucus layer (2, 3). The thickness of the inner attached mucus
layer ranges between 50 and 100 m (depending on species)
and is gradually converted to the outer layer (1, 3). Both the
inner and the outermucus layers are primarily composed of the
MUC2 mucin, a large glycoprotein whose central regions con-
sists of PTS domains rich in the amino acids proline, threonine,
and serine that afterO-glycosylation result in the typical mucin
domain. The N- and C-terminal domains are less glycosylated,
are stabilized by numerous disulfide bonds, and make the
MUC2 C-terminally dimeric and N-terminally trimeric (4, 5).
Because the MUC2 monomer is 2.5 MDa in mass, this poly-
merization generates enormous net-like structures (3, 6). The
MUC2 polymer normally remains intact in the inner mucus
layer and expands to form the outer mucus layer (6).
The human colon has a high number of commensal bacteria,
some of which live in symbiosis with their host (7). The number
of microorganisms in the adult intestine is estimated to be
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1013–1014, a number well exceeding the number of cells in the
host body (8). Themicrobial community is diverse and complex
and comprises approximately l,000 bacterial species (9). The
majority of these organisms belong to the phyla Bacteroidetes
and Firmicutes families and are found in the large intestine
where they live in the outer loosemucus layer (2). Interestingly,
the inner mucus layer normally acts as a barrier that does not
allow bacteria to reach the epithelial cells and thus limits the
direct contact between the host and the bacteria. However,
when there is no mucus layer, as in the Muc2-null mice, the
direct contact between bacteria and epithelium triggers severe
inflammation (1). The pathogenic bacterium Citrobacter
rodentium has specific mechanisms to colonize the firmmucus
layer in mice causing colitis (10). O-Glycosylation of serine or
threonine with GalNAc, often called mucin-type glycosylation,
is mediated by a family of 20 polypeptide N-acetylgalactosami-
nyltransferases (GalNAc-Ts)3 (11). These GalNAc-Ts have dis-
tinct but partly overlapping acceptor substrate specificities and
are differentially expressed in cells and tissues, which provides
for differential and dynamic regulation of O-glycosylation of
proteins and the specific sites of O-glycan attachment on pro-
teins. Specific GalNAc-Ts either initiate O-glycosylation or
complete attachment of O-glycans in protein regions with
denseO-glycosylation such as those found onmucins (11). Sev-
eralGalNAc-Ts are linked to diseases, and themolecularmech-
anism for deficiency of one GalNAc-T, GalNAc-T3, has been
clarified and shown to cause the disease familial tumoral calci-
nosis caused by a lack of site-specificO-glycosylation of a single
Thr residue in a proprotein convertase inactivation site of the
factor fibroblast growth factor FGF23 (12, 13). Further studies
have demonstrated more general roles of site-specificO-glyco-
sylation adjacent to sites of regulated proteolytic protein pro-
cessing (14). Entamoeba histolytica is a parasite that is able to
invade the host mucosa and pass over the inner mucus layer.
E. histolytica was shown to secrete a cysteine protease that
cleaves the MUC2 protein core at a specific site between the
second mucin domain and its disulfide bond-stabilized C ter-
minus (15). This cleavage disrupts the MUC2 polymer and
allows the amoeba to penetrate the inner mucus layer.We then
asked whether there are bacteria in the colon that also can
cleave the MUC2. We initially analyzed the typical commensal
bacteria Lactobacillus brevis, Lactobacillus plantarum, Lacto-
bacillus bulgaricus, andBifidobacterium lactis for secreted pro-
teases that could cleave and dissolve the MUC2 mucin protein
core, but none of these showed any proteolytic activity (16).
This is in linewith the bacteria having their habitat in the lumen
and outer mucus layer and lacking mechanisms of penetrating
and utilizing the inner mucus layer. In search of other bacteria
that can be found in the colonic flora and that could potentially
produce MUC2 specific proteases, we tested whether Porphy-
romonas gingivaliswas such a candidate.P. gingivalisbelongs to
the phylum Bacteroidetes and is a nonmotile, Gram-negative,
rod-shaped, anaerobic bacterial pathogen. The bacterium can
be found in colon but ismore abundant in the oral cavity, where
it is implicated in the pathogenesis of periodontitis because of
its ability to deter antibacterial attack by the immune system,
and triggers a chronic inflammatory reaction via secretion of a
family of cysteine proteases called gingipains (17). We now dem-
onstrate that the P. gingivalis Arg-gingipain B (RgpB) is able to
cleave theMUC2mucin at a specific site thatwill cause themucus
polymer to dissolve. Furthermore, we show that this cleavage site
can be selectively blocked by site-specific O-glycosylation of the
Thr located adjacent to the cleavage site by GalNAc-T3.
EXPERIMENTAL PROCEDURES
Bacteria and Culture Conditions—P. gingivalis W83 (18)
obtained from CCUG (Culture Collection University of
Gothenburg, Gothenburg, Sweden) and mutants Kgp,
RgpA, and RgpA/RgpB were plated on Brucella agar (BBL
Microbiology Systems) enriched with 5% defibrinated horse
blood, 0.5% hemolyzed blood, and 5 g/ml menadione and
incubated overnight at 37 °C in anaerobic jars with 95% H2 and
5% CO2. Selected colonies were cultured anaerobically in basal
medium-PY-peptone yeast extract (1.0 g of peptone, 1.0 g of
yeast extract, 0.4 ml of resazurin solution, 4 ml of salt solution,
100 ml of distilled water, and 0.05 g of cysteine HCl-H2O) for
96 h at 30 °C. The bacteria were pelleted by centrifugation at
4,000 rpm for 30 min, and the supernatants were carefully
removed and used in the subsequent studies.
Antibodies and Proteins—TheMUC2N3 andMUC2C2 poly-
clonal antisera were generated against the MUC2 peptides
CPKDRPIYEEDLKK and CIILRPDNQHVILKPGDFK, respec-
tively, as described previously (4, 5). Goat anti-rabbit immuno-
globulin coupled to alkaline phosphatase (DAKO) was used as
secondary antibody for all immunoblotting. The design and
production of the recombinant MUC2 N and C termini, con-
sisting of residues 1–1792 and 4198–5179, respectively, of the
humanMUC2 protein N terminus flanked byGFP and theMyc
tag, are described in detail elsewhere (5, 19). Purified gingipain
RgpB from the P. gingivalis strain HG66 was produced as pre-
viously described (20, 21).
MUC2 Proteolytic Cleavage by P. gingivalis Secretions and
Purified RgpB—All of the protease assays were performed as
follows. Secretions from P. gingivalis or 200 ng of RgpB were
preincubated in Dulbecco’s PBS in the presence or absence of
the cysteine specific protease inhibitor E-64 (100 M) (Roche
Applied Science) at 37 °C for 30min, followed by the addition of
1g of purified recombinantMUC2N or C terminus and over-
night incubation at 37 °C. Controls were incubated in Dulbec-
co’s PBS without the addition of P. gingivalis secreted material
or RgpB. The digestion was terminated by the addition of 2
SDS-PAGE sample buffer (4% SDS, 125 mM Tris-HCl, pH 6.8,
30% (v/v) glycerol, 5% (v/v) bromphenol blue, supplemented
with 200mMDTT for reducing conditions) and heated at 95 °C
for 5 min. The samples were directly analyzed by SDS-PAGE
using precision protein standards (Bio-Rad) as markers. West-
ern blottingwas performed as described (15). After transfer and
blocking the blots were incubated with anti-MUC2 N3 or C2
antibodies and developed using nitroblue tetrazolium/5-bro-
mo-4-chloro-3-indolyl phosphate (Promega).
Fractionation of the Secretions from P. gingivalis—P. gingiva-
lis cultured supernatant was prefiltered (0.45-mmini capsule;
3 The abbreviations used are: GalNAc-T, N-acetylgalactosaminyltransferases;
TMPP, (N-succinimidyloxycarbonyl-methyl)tris(2,4,6-trimethoxyphenyl)
phosphonium bromide.
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Pall) and dialyzed (Spectra/Por Dialysis Membrane, molecular
weight cutoff of 6,000–8,000; Spectrum Laboratories) three
times against 20 mM Tris-HCl, pH 8.0. The dialyzed medium
was fractionated by ion exchange chromatography (MonoQ
HR 5/5; GE Healthcare). The samples were loaded in buffer A
(20 mM Tris-HCl, pH 8.0) and eluted using a linear 45-min
gradient toward 100% buffer B (1 M NaCl in 20 mM Tris-HCl,
pH 8.0), and the fractionswere collected at 2-min intervals. The
protease activity in each individual fraction was determined by
incubation with MUC2-C followed by SDS-PAGE and immu-
noblotting using the anti-MUC2C2 antibody. Aliquots of the
active fractions were analyzed by SDS-PAGE under reducing
conditions and stained using Imperial protein stain (Thermo)
for subsequent protein identification by mass spectrometry.
In-gel Digestion, Mass Spectrometry, and Data Analysis—
Bands of interest were excised from the SDS-PAGE gels and
washed for 20 min with 25 mMNH4HCO3 in 50% CH3CN. The
gel pieces were dried by vacuum centrifugation, reconstituted
in 20 l of 10 mMDTT in 25 mMNH4HCO3, and incubated for
1 h at 56 °C. The remaining solution was removed, 20 l of 55
mM iodoacetamide in 25 mM NH4HCO3 was added, and the
samples were left for 30 min at room temperature. The gel
bands were washed twicemore, dried, and reconstituted in 7 l
of trypsin or endoproteinase Lys-C (10 ng/l) (Promega) in 25
mMNH4HCO3 and incubated at 37 °C overnight. The digestion
reaction was quenched by the addition of 25 l of 50% CH3CN,
1% CH3COOH, and the peptides were extracted twice. Pooled
supernatants were dried and resolved in 15 l of 0.1% formic
acid prior MS analysis. The samples were analyzed by nLC-ESI
MS/MS (LTQOrbitrap XL ETD; Thermo), and 2l of the sam-
ple was injected and separated online as described earlier (22).
After loading in 0.2% formic acid, the peptides were separated
using a 15- or 35-min 10–50% gradient toward acetonitrile.
The shorter gradient was used for analyses of the 29-mer pep-
tide, whereas for cleavage site determination and protein iden-
tification, the longer gradient was applied. Themass spectrom-
etry analysis was performed in a data-dependent mode with
automatic switching between scan modes, performing MS/MS
on the top sixmost intense ions per precursor scan.MS scans in
themass range ofm/z 400–2,000were obtained in theOrbitrap
and MS/MS fragmentation scans in the LTQ ion trap using
collision-induced dissociation. Selected sequenced ions were
dynamically excluded for 30 s. Raw spectral data were con-
verted using extract_msn.exe (version 3.2 Thermo), identified
by MASCOT (version 2.2.04 Matrix Science) and searched
against the SwissProt protein database (release 57.12) with the
following parameters: (i) one missed cleavage Trypsin or LysC;
(ii) tolerance 5 ppm (precursor), 0.5 Da (fragment ions); (iii)
charge state 2, 3, 4; (iv) carbamidomethyl cysteine (fixed),
oxidized methionine (variable); and (v) taxonomy other bacte-
ria (41,537 entries). Additional parameters were included for the
cleavage site determination: a variable TMPPmodification on the
peptide N terminus, semitryptic cleavage, and searched against
human (20,242 entries) supplementedwith our in-houseMUCIN
database available at our website containing the recombinant
MUC2C-terminal sequences.Protein identificationswereconsid-
ered if based on at least two unique peptide identificationswith an
ion score of 20.
Identification of GalNAc-Ts Expressed in Human Colonic
Epithelia by Mass Spectrometry—Two sigmoid biopsies were
obtained from patients referred to routine colonoscopy in
which the colonic mucosa appeared macroscopically normal.
Approval was granted by the Human Research Ethical Com-
mittee of the University of Gothenburg, and written informed
consent was obtained from all study subjects. Epithelial cells
were isolated as described previously (23) with slight modifica-
tions. Briefly, the tissues were washed in PBS for 5min followed
by addition of PBS containing 3 mM EDTA and 1 mM DTT and
incubated at 4 °C for 60 min while being gently shaken. The
solution was replaced with fresh PBS, and epithelial cells
were dissociated from the tissue by vigorous shaking for 30 s.
The remaining tissue was removed from solution, and the cells
were pelleted by centrifugation at 500 rpm, resolved in 500l of
2 MNaCl, 1mMEDTA in 10mMHEPES, pH7.4, and lysed by tip
probe sonication. The membrane proteins were extracted as
described (24), with all centrifugation steps performed at
100,000  g for 20 min. The proteins were solubilized in 0.1 M
DTT, 4% SDS in 0.1 M Tris-HCl, pH 7.6, and digested using
trypsin (Promega) according to the filter-aided sample prepa-
ration method (25) on a 10,000-kDa cutoff filter (NanoSep;
Pall). Recovered peptides were fractionated using ZIC-HILIC
(3.5 m; SeQuant, Sweden) packed in a fused silica capillary
(150 mm  0.32 mm inner diameter) with 5 mM ammonium
acetate in 0.5% formic acid, 95% acetonitrile as mobile phase A
and 5 mM ammonium acetate as mobile phase B. Elution was
performed with a gradient between 0 and 50%; six fractions
were collected, dried under vacuum, and reconstituted in 15 l
of 0.1% C2HF3O2. Both mass spectrometry and spectral data
analysis were performed as described.
TMPPLabeling of ProteolyticallyCleavedMUC2CTerminus—
For determination of the proteolytic cleavage site, the -amine
groups of MUC2-C were specifically labeled using (N-succin-
imidyloxycarbonyl-methyl)tris(2,4,6-trimethoxyphenyl) phos-
phonium bromide (TMPP) after incubation with either super-
natants from P. gingivalis, RgpB or PBS. The pH of the samples
was first titrated to 8.2 by the addition of 0.1 M Na2HPO4, after
which 5 l of freshly prepared 20 mM TMPP reagent (Sigma)
resolved in 70% EtOH was added. The reaction was quenched
after 1 h by the addition of 1 l of 0.1% hydroxylamine, and the
samples were analyzed by SDS-PAGE under reducing condi-
tions and stained using Imperial protein stain (Thermo) fol-
lowed by in-gel tryptic digestion and mass spectrometry
analysis.
Edman Sequencing of the Major MUC2 C-terminal Cleavage
Products—Recombinant MUC2-C (10 g) was incubated with
5 g of the secreted material from P. gingivalis or 200 ng of
RgpB at 37 °C overnight. The samples were separated by SDS-
PAGE, blotted to PVDF membrane, and stained with Imperial
protein stain (Thermo). Bands of interest were excised and
sequenced by Edman degradation on a Procise 492 protein
sequencer (Applied Biosystems).
Inhibition of RgpB-mediated Proteolysis ofMUC2 by Site-spe-
cific O-Glycosylation—The effect of GalNAc O-glycosylation
on RgpB cleavage of MUC2 was determined by in vitro assays
using the synthetic peptide AWTPTPTPLSTPSIIRTTGLR-
PYPSSVLI (hMUC2, amino acid 4306–4335) (Schafer-N) cov-
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ering the identified cleavage site IR2TT. The peptide was gly-
cosylated using recombinant human GalNAc-Ts as described
earlier (26) using either GalNAc-T1, -T2, -T3, -T4, -T5, -T7, or
-T12. Glycopeptides were subsequently glycosylated by T7 or
T12. The sites of GalNAc incorporation were characterized by
mass spectrometry (LTQ-Orbitrap XL ETD; Thermo) after 30
min of digestion with trypsin using direct syringe infusion (2
l/min). Fragmentation spectra were generated using electron
transfer dissociation with fragment ion detection in the
Orbitrap. For inhibition studies, the glycosylated peptides were
diluted in PBS to a concentration of 1 g/l, and 1 l was
incubated for 5 min at 37 °C with 1 l of P. gingivalis secretion,
RgpB (10 ng/l) or 1l of E. histolytica secretion with the addi-
tion of 8l of PBS. The nonmodified peptide was treated under
identical conditions. The reaction was quenched by addition of
100 l of 0.2% formic acid and directly analyzed by nLC-ESI
MS/MS using a 15-min gradient. The data were interpreted
manually using Xcalibur software (version 2.1; Thermo).
Immunohistochemistry onColon Sections—Sectionswere cut
from frozen blocks of five case patients with normal appearing
mucosa adjacent to colon adenocarcinomas at a thickness of 5
m and mounted on gelatin-coated slides. Every fifth section
was stained by hematoxylin-eosin and used as reference during
evaluation. The sectionswere fixed in 10% cold buffered neutral
formalin for 15 min and incubated with anti-GalNAc-T3 mAb
UH5 (2D10) at 4 °C overnight (27). BoundmAbs were detected
with FITC-conjugated rabbit anti-mouse immunoglobulin
absorbed with human serum (F-261; Dako Denmark). In one
case, a double-layer immunofluorescence technique was used.
The first layer was mixed with a polyclonal antibody against
human MUC2 non-O-glycosylated TR 1:500, and after block-
ing with goat serum (1:10), the second layer was replaced with a
mixture of FITC-conjugated goat anti-mouse immunoglobulin
(115-545-166; Jackson ImmunoResearch, Baltimore, MD)
(1:200) and goat anti-rabbit immunoglobulin 115295-144
(Jackson) (1:200) and mounted with Vectashield containing
DAPI (Vector Laboratories, Burlingame, CA). Fluorescence
microscopy was performed using a Zeiss Axioskop 2 plus, and
confocal images were obtained with an LSM780 (Carl Zeiss).
Generation of CHO K1 Cells Coexpressing MUC2-C and
GalNAc-T3—A CHO K1 clone stably expressing SMG-
MUC2C (5) was cultured in Iscove’s modified Dulbecco’s
medium  10% fetal bovine serum (Lonza, Verviers, Belgium)
and transfected with pcDNA3.1zeo/GalNAc-T3 using Lipo-
fectamine 2000 (Invitrogen). Stable clones were selected in the
presence of both 250 g/ml Geneticin (Invitrogen) and 250
g/ml Zeocin (Invitrogen). Spent culture supernatant without
serum fromone clone expressing high levels of GalNAc-T3was
collected and used in the RgpB cleavage assay as described
above. 20 ng of RgpB was added to 2 g of purified MUC2-C
and incubated for 5, 15, or 30 min at 37 °C before analysis by
nonreducing SDS-PAGE as described.
RESULTS
Degradation of the MUC2 C-terminal Region by P. gingivalis
Secreted Cysteine Proteases—We have previously shown that
some typical commensal bacteria do not have any proteolytic
activity on the MUC2 mucin (16). However, we screened some
potentially more aggressive bacteria for MUC2 degradation
and found that P. gingivalis was such a candidate. To specifi-
cally analyze this, we earlier generated the recombinant trim-
eric MUC2-N and dimeric MUC2-C proteins that contained
the N- or C-terminal cysteine-rich parts (N terminus is 1396
amino acids and C terminus 981) of the MUC2 as outlined in
Fig. 1A (5, 19). Cultured supernatants from bacteria were incu-
bated with the recombinant MUC2-N or MUC2-C, and the
cleaved products were analyzed by immunoblotting using
either anti-MUC2N3 or anti-MUC2C2 antisera. These studies
showed that secretions of P. gingivalis did not affect theMUC2
FIGURE 1. The C terminus of the MUC2 mucin can be degraded by cysteine
proteases secreted by P. gingivalis. A, schematic presentation of the
domain structure of the MUC2 mucin and recombinant fusion proteins. B and
C, gel electrophoresis and immunoblot analysis of the MUC2 C terminus incu-
bated with P. gingivalis secreted material. The MUC2-C was incubated over-
night with secretions from P. gingivalis W83 with or without preincubation
with E-64, purified protease RgpB, or buffer alone. B, the samples were ana-
lyzed under nonreducing conditions by Western blotting with anti-MUC2C2.
The W83 secretion-treated bands show a decrease in molecular mass com-
pared with the control and E-64 inhibited. C, analyses under reducing
revealed two distinct bands at 130 and 65 kDa; identical results were obtained
using the purified enzyme RgpB. neg. ctrl., negative control.
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N terminus (data not shown) but degraded theMUC2-C dimer.
This observation was investigated further.
MUC2-C incubated with the secreted material from the
P. gingivalis strain W83 was analyzed by SDS-PAGE under
nonreducing conditions and immunoblotted using the anti-
MUC2C2 antiserum. Because the MUC2-C is a large dimer
with an estimated mass of 470 kDa (19), it migrated slowly,
whereas the cleaved productmigrated further into the gel, indi-
cating the presence of secreted proteases capable of digesting
MUC2-C (Fig. 1B).WhenMUC2-Cwas instead analyzed under
reducing conditions, it migrated as a monomer at 250 kDa
(Fig. 1C). When the cleaved products were analyzed under
reducing conditions two bands were seen, one at 65 kDa and
one at 130 kDa (Fig. 1C). Preincubating the secretions with
E-64, the diagnostic inhibitor of papain-like cysteine proteases,
could abolish this proteolytic cleavage. E-64 reversibly inhibits
arginine-gingipains (RgpA and RgpB) but has no effect on Kgp
activity (21). This suggests that cysteine proteases other than
Kgp are involved in MUC2-C cleavage. The lower band
observed in the control sample at 150 kDa is due to the auto-
catalytic degradation of the GDPH sequence (29).
Identification of the Cysteine Proteases in P. gingivalis Secre-
tions Responsible for Cleavage of the MUC2 C Terminus—To
determine the nature of the protease that cleaved the MUC2,
the secreted products were separated by ion exchange chroma-
tography, and the fractions were tested for proteolytic activity
on the MUC2-C (supplemental Fig. S1). The products were
analyzed by SDS-PAGE and stained with the anti-MUC2C2
antiserum. Fractions 8–12 showed proteolytic activity indi-
cated by loss of the full length and the appearance of the band at
65 kDa representing themajor cleavage fragment. ActiveP. gin-
givalis fractions were analyzed by SDS-PAGE, and stained
bands were excised for subsequent analysis by mass spectrom-
etry. Protein database searches identified various P. gingivalis
proteins, of which three were known proteases (supplemental
Table S1). The proteases RgpA, RgpB (Arg-gingipain A and B),
and KgP (Lys-gingipain) were identified in all active fractions.
All three are gingipains and thus cysteine proteases, confirming
the initial protease inhibition results (Fig. 1C). RgpA and RgpB
belong to the gingipain family of broad specific proteases and
cleave at the P1 position of Arg (30), whereas the gingipain Kgp
is a Lys-specific protease (31). To identify which gingipain was
involved in degradation of theMUC2-C, secretions fromP. gin-
givalis mutant strains lacking one or two of the proteases
(Kgp, RgpA, and RgpA/RgpB) were incubated with
MUC2-C and analyzed under reducing and nonreducing con-
ditions by immunoblotting using the anti-MUC2C2 antiserum
(Fig. 2). The wild type strain W83 and mutants for Kgp and
RgpA degraded the protein as observed by the appearance of
the 65-kDa fragment or loss of full-length MUC2-C under
reducing and nonreducing conditions, respectively (Fig. 2).
Proteolytic activity was observed in the two mutants Kgp and
RgpA, suggesting that the protease responsible for cleavage
was RgpB. The double mutantRgpA/RgpB further confirmed
this because the cleavage was completely abolished. RgpB has a
broad pH optimum in the range of pH 9.5 (100% activity) down
to pH 5 (50%), which covers the pH range of the colon (20).
To further demonstrate that theRgpB is able to cleaveMUC2
in the same way as the culture supernatants, purified RgpB was
incubated with MUC2-C, and the products were analyzed by
SDS-PAGE under nonreduced and reduced conditions (Fig. 1,
B and C). The results show the same 65-kDa fragment
appeared, thus confirming that the P. gingivalis gingipain RgpB
is able to cleave the MUC2 mucin in its C-terminal end.
Characterization of theMUC2C-terminal Cleavage Products—
Degradation of MUC2 after incubation with the P. gingivalis
supernatant or RgpB suggested specific cleavage sites inMUC2.
To analyze this aspect, the P. gingivalis culture supernatant was
incubated withMUC2-C, the products were separated by SDS-
PAGE, and the bands were excised and analyzed by Edman
sequencing. The results of the 130-kDa band showed an N ter-
minus with the sequence 4322TTGLR, and the 65-kDa band
showed anN terminuswith the sequence 4566QAVAL (Fig. 3A),
both with arginine at position P1.
To confirm the cleavage, an -amine specific labeling tech-
nique was applied prior to mass spectrometry analyzes. The
TMPP labeling technique ensures that the peptide remains in
its ionic state required for sequencing and increases its overall
hydrophobicity, which separates it from most peptides during
reverse phase chromatography (32, 33). The RgpB-treated
MUC2-C product was TMPP-labeled prior to gel separation by
SDS-PAGE and stained with Coomassie, and both the 130- and
65-kDa bands were in-gel digested using trypsin. Extracted
peptides were analyzed by nLC-ESI MS/MS, and the spectral
data were searched for semitryptic peptides. The TMPP-mod-
ified peptide TTGLR eluting at 36.2 min with anm/z of 560.25
(2) was identified as the neoN terminus of theMUC2 protein
at amino acid residue 4322 in the 130-kDa band (Fig. 3B). The
identified peptide was labeled at its N terminus, and the frag-
mentation spectra revealed the distinct reporter ion TMPP-
CHCO atm/z 573.18 (1) and a predominant b-ion series as
induced by theTMPP labeling (32). Themodified peptide could
FIGURE 2. Immunoblot analysis of P. gingivalis secretions from different
gingipain mutant strains. MUC2-C was incubated overnight with secretions
from three different mutants of P. gingivalis and subjected to immunoblot-
ting using anti-MUC2C2. The immunoblots show that under both reducing
(A) and nonreducing (B) conditions, Kgp and RgpA mutants show identical
band patterns, compared with the wild type (W83) where a distinct band at 65
kDa indicates the presence of the protease. The double RgpA/RgpB mutant
shows identical results as the control, indicating that RgpB is the protease
involved in MUC2-C degradation. neg. ctrl., negative control.
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not be identified in the control MUC2 C-terminal band. The
N-terminal peptide in the 65-kDa band could not be identified
potentially because of its increased hydrophobicity induced by
the TMPP label. However, protein digestion using the lysine
specific enzyme Lys-C identified the peptide QAVALPYK at
m/z 445.26 (2) corresponding to the N terminus in the
65-kDa band. Thus, both cleavage sites were identified by mass
spectrometry and Edman sequencing.
RgpB therefore cleaves the MUC2 mucin at two positions.
The MUC2-C has a high number of Cys amino acids that form
multiple disulfide bonds, rendering this part of the protein sur-
prisingly protease-resistant. The 4566QAVAL cleavage is within
such a region. On the other hand, the 4322TTGLR cleavage is
located N-terminally prior to the first Cys of the MUC2 C ter-
minus after the large mucin domain. Cleavage at IR2TT is
therefore expected to cause a separation of the two products as
shown for E. histolytica (15), whereas when cleaved at the
NR2QA, the protein is still held together via disulfide bonds.
This interpretation is consistent with the relative small shift in
size when analyzed on nonreducing gels where the C-terminal
part of MUC2-C is still held together as a dimer. As for E. his-
tolytica, the P. gingivalis cleavage at the IR2TT is therefore
expected to disrupt the MUC2 polymer network.
O-Glycosylation of MUC2 Adjacent to the IR2TT Cleavage
Site—Because the RgpB cleavage site has two adjacent Thr res-
idues that could potentially be O-glycosylated, we determined
whether these sites could be glycosylated in vitro, whether gly-
cosylation would block RgpB cleavage, and whether the
required GalNAc-Ts were expressed in the colon. The reper-
toire of GalNAc-Ts expressed in human colon is not fully elu-
cidated (11). To characterize which isoforms are expressed in
the colon, we first used proteomics analysis on epithelial cells
isolated from human colonic biopsies. Analysis of the mem-
brane proteome identified expression of seven GalNAc-Ts (T1,
T2, T3, T4, T5, T7, and T12) (Table 1).
To test whether the 4320IR2TT region can be glycosylated
and whether this can inhibit RgpB cleavage, a synthetic 29-mer
peptide covering the cleavage region with and containing 10
potential O-glycosylation sites (MUC2-pep 1, AWTPTPTPL-
STPSIIRTTGLRPYPSSVLI, possible O-glycosylation sites
underlined) was glycosylated in vitro by the recombinant
human GalNAc-Ts that were found to be expressed in the
colon. GalNAc-T1 added one to four GalNAc residues, where
the addition of three GalNAcs was the major product (Fig. 4).
GalNAc-T2 incorporated GalNAc residues at Thr4311 and
Thr4315; however, none of these sites were predicted to affect
the RgpB cleavage. Glycosylation with GalNAc-T3 showed an
incorporation of the highest number of GalNAc residues (up to
6), with the addition of three GalNAc residues comprising the
major product (supplemental Fig. S3).Mass spectrometry anal-
ysis of the tryptic digest of the GalNAc-T3 glycosylated peptide
with the addition of three to five GalNAc residues showed that
the Thr4325 was occupied at the P2 position for the RgpB cleav-
age site (supplemental Fig. S2). GalNAc-T5 added only one res-
idue to the peptide. Supplemental Fig. S3 shows the obtained
glycopeptides where the peak intensities indicate the relative
amount of each glycoform. The GalNAc-T7 and -T12 enzymes
did not add any GalNAc to the naked peptide. However, prior
GalNAc modifications on the peptide by GalNAc-T3 allowed
GalNAc-T7 toadduptonineadditionalGalNAc residues tonine
of ten potential sites. Interestingly GalNAc-T12, which has
been associated with colon cancer (34), only added one or two
GalNAcs to the GalNAc-T5 primed peptide (Fig. 4). To sum-
marize, onlyGalNAc-T3was able to add aGalNAc to one of the
two Thr adjacent to the RgpB cleavage site.
Inhibition of the RgpB Cleavage of MUC2-C by Site-specific
O-Glycosylation—The effect of GalNAc O-glycans adjacent to
the identified RgpB cleavage site IR2TT was addressed using
the in vitro glycosylated peptides. Both glycosylated and non-
glycosylated peptides were incubated for 5 min with purified
RgpB, after which the reaction was quenched. Mass spectrom-
etry analysis of the control and RgpB-treated nonglycosylated
peptide showed a single peak for the intact 29-mer peptide (Fig.
5A) and two peptide fragments AWTPTPTPLSTPSIIR and
TTGLRPYPSSVLI (Fig. 5B) after incubation with the protease.
In contrast, incubation of the GalNAc-T3 glycosylated peptide
FIGURE 3. Neo N-terminal sequences after proteolytic cleavage as deter-
mined by both Edman degradation and mass spectrometry. A, schematic
representation of the human MUC2-C corresponding to the region directly
after the PTS domain (amino acids 4198 –5179) flanked at the N-terminal side
by GFP and the Myc tag. The two cleavage sites identified by Edman sequenc-
ing at2TTGLR and2QAVAL are highlighted, plus the peptide TTGLR and
QAVALPYK as confirmed by mass spectrometry analysis. The localization of
the epitope for the anti-MUC2C2 polyclonal antibody is highlighted at the far
C terminus. B, fragmentation spectra of the TMPP-labeled peptide TTGLR. The
MUC2 C terminus was incubated with P. gingivalis secretions and labeled
using TMPP specifically derivatizing the newly formed N terminus. Mass spec-
trometry analysis identified the peptide TTGLR labeled at its N terminus, indi-
cating proteolytic cleavage at this site. The TMPP-CHCO reporter ion is indi-
cated in red, b-ions are in blue, and y-ions are in red.
TABLE 1









Q10472 GALNT1 2 4.7
Q10471 GALNT2 5 8.4
Q14435 GALNT3 9 18.8
Q8N4A0 GALNT4 8 14.4
Q7Z7M9 GALNT5 6 7.6
Q86SF2 GALNT7 11 19.3
Q8IXK2 GALNT12 7 15.1
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containing three GalNAc residues with the RgpB protease did
not result in cleavage, and only the intact glycopeptide was
found after incubation (Fig. 5C). Glycopeptides produced by
any of the other single GalNAc-Ts were all degraded by the
RgpB protease. This indicated that selective glycosylation of
Thr4322 by GalNAc-T3 rendered the glycopeptide resistant to
degradation. The combination of GalNAc-T3 and -T7 pro-
duced a highly glycosylated peptide with nine of ten sites occu-
pied that was also fully resistant to proteolysis (Fig. 5D).
These results suggest that a single GalNAc residue attached
to the second Thr (Thr4322) is the only modification that is
required to render the IRTT sequence completely resistant to
RgpB cleavage. The effect of E. histolytica secreted material on
both the nonmodified and GalNAc-T3-modified peptide was
also studied (15). This showed that this site-specific glycosyla-
tion also inhibited the secreted E. histolytica protease. In the
nonmodified peptide, the cleavage site 4320RT2TG was con-
firmed. In addition, exoprotease activity was observed, result-
ing in various truncated peptides (supplemental Fig. S4A). The
GalNAc-T3-modified peptide became resistant to both endo-
and exoprotease activities (supplemental Fig. S4B).
Localization of GalNAc-T3 to Goblet Cells in Human Colon—
Because the GalNAc-T3 enzymewas the only GalNAc-T found
in the colon epithelium that could modify and block the RgpB
cleavage site in MUC2, we confirmed that the transferase was
expressed in the Golgi apparatus of colonic goblet cells. Immu-
nohistology of human colon tissue with an anti-GalNAc-T3
mAb revealed staining of both enterocytes and goblet cells (Fig.
6). The colocalization of MUC2 and GalNAc-T3 was further
confirmed by staining goblet cells with the antiserum anti-
MUC2TR that only recognizes the endoplasmic reticulum-
early Golgi non-O-glycosylated MUC2 precursor. The colocal-
ization of MUC2 and GalNAc-T3 suggests that MUC2 is
O-glycosylated at the IRTT sequence, because in vitro analysis
of GalNAc-T substrate specificities correlate well with in vivo
glycosylation (11).
Expression of GalNAc-T3 in CHO-K1 Cells Secreting
MU2C-CMakes the Protein Resistant for RgpB—The recombi-
nant MUC2-C used in these studies was produced in CHO-K1
cells. Recent transcriptome analysis of this cell line revealed
that only GalNAc-T2, -T7, -T11, and -T20were expressed (35).
This observation and the observed RgpB cleavage of MUC2-C
suggest that the Thr4322 is not glycosylated in the recombinant
protein. CHO-K1 cells coexpressingMUC2-C and GalNAc-T3
were generated to determine whether this made MUC2 resis-
tant to cleavage (Fig. 7A). The MUC2-C secreted from these
cells was incubated for various time points with the recombi-
nant RgpB, and the products were analyzed by nonreducing
SDS-PAGE stained by Coomassie (Fig. 7B). TheMUC2-C from
cells expressing GalNAc-T3 showed full resistance to cleavage
by RgpB. The results suggest that MUC2-C produced in
CHO-K1 cells is not glycosylated at Thr4322 and that coexpres-
sionwithGalNAc-T3 can completely inhibit the degradation of
MUC2 by RgpB.
DISCUSSION
The anaerobic bacterium P. gingivalis was found to secrete a
protease capable of cleaving the MUC2 mucin at two specific
sites in the C-terminal region, one which will cause the MUC2
polymeric network to dissolve. Of the three gingipains secreted
by P. gingivalis, it was only RgpB that was able to cleave the
MUC2mucin. In contrast, the 1,400-amino acid-longN-termi-
nal part of MUC2 was not affected by RgpB. The central region
of MUC2 is 2,800 amino acids long and contains two mucin
domains that are highly glycosylated. Because of this glycosyl-
ation, the mucin domains are highly resistant to proteases and
are not expected to be cleaved by proteases (36). The 980-
amino acid-long C-terminal part of MUC2 showed two cleav-
age sites. One is localized to the NR2QA sequence within the
VWD4 domain where the cleavage site is surrounded by
numerous cysteines that are involved in disulfide bond forma-
tion (Fig. 1A). The NR2QA cleavage does not disrupt the pro-
tein as suggested by the analysis of the nonreduced cleavage
products. Thus, a cleavage at this site will not disrupt the disul-
fide bond-stabilized MUC2 polymer. However, the second
cleavage site is localized prior to the first cysteine in theMUC2
C-terminal VWD4 domain and is therefore not stabilized via
FIGURE 4. Analysis of in vitro O-glycosylation sites by different GalNAc-T
isoforms on a 29-mer MUC2 peptide. The peptide corresponding to the
amino acids 4306 – 4335 were O-glycosylated with the GalNAc-Ts T1, T2, T3,
T4, and T5, followed by the glycopeptide specific GalNAc-T7 or -T12. Sites
were characterized by mass spectrometry using electron transfer dissociation
fragmentation. The sites of GalNAc incorporation are highlighted and marked
with asterisks when added by T7 or T12. The RgpB cleavage site is indicated in
the sequence at the IR TT position. Sites of incorporation could not be
assigned for the GalNAc-T1 and -T2 glycosylated peptides (marked A and B in
yellow squares). Glycosylation by the combination of GalNAc-T3 with -T7
added on average eight GalNAc residues to the peptide where modified sites
could not be unambiguously assigned due to the complexity (marked C in a
yellow squares).
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disulfide bonds. Proteolytic cleavage at this site is therefore
expected to disrupt the polymeric network of theMUC2mucin.
TheMUC2mucin is also cleaved by secreted cysteine prote-
ase from the colon pathogen E. histolytica (15). One of the
cleavages by E. histolytica protease was within the VWD4
domain at the KT2TP sequence 817 amino acids further
C-terminal to the here identified P. gingivalis cleavage site.
Both of these E. histolytica and P. gingivalis cleavages were sta-
FIGURE 5. Extracted ion chromatograms of the mass spectrometry analysis on the 29-mer synthetic peptide modified by GalNAc-T3 and digested with
RgpB. A, control incubated for 5 min at 37 °C in PBS; only the noncleaved peptide at m/z 1041.58 (3) was observed. B, incubation with RgpB resulted in
cleavage at the IR43202TT position as confirmed by MS/MS sequencing of the two peptides AWTPTPTPLSTPSIIR and TTGLRPYPSSVLI. C, extracted ion
chromatograms of the GalNAc-T3 glycosylated peptide after 5 min of incubation with RgpB. The peptide was not affected as observed by the peak at m/z
1245.32 (3) of the full peptide with three GalNAc residues. D, the GalNAc-T3 glycosylated peptide further glycosylated by GalNAc-T7. The eluting peptide
peak at m/z 1584.89 (3) of the full peptide with eight GalNAc residues was not cleaved by RgpB.
FIGURE 6. GalNAc-T3 is colocalized with the MUC2 mucin in human colon
goblet cells. GalNAc-T3 was stained with mAb 2D10, the MUC2 (unglyco-
sylated) was stained with the anti-MUC2TR antiserum, and the nuclei were
stained with DAPI.
FIGURE 7. RgpB cleavage of MUC2 C-terminal construct coexpressed with
or without the GalNAc-T3 transferase. A, costaining of the MUC2 C termi-
nus in green, GalNAc-T3 transferase in red, and the nuclei in blue. The Golgi
localized fraction of the MUC2 C terminus shows a clear localization with the
transferase. B, MUC2-C produced in CHO cells with () or without ()
GalNAc-T3 was incubated for 5, 15, or 30 min at 37 °C with RgpB. SDS-PAGE
analysis visualized by Coomassie staining. MUC2-C expressed in CHO cells
without GalNAc-T3 was completely degraded after 30 min as observed by the
loss of the upper band, whereas the MUC2-C coexpressed with GalNAc-T3
remained intact. ctrl., control.
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bilized with disulfide bonds, and the products did not separate.
The other RgpB cleavage site was identified at the IR2TT
sequence. Interestingly, this is only one amino acid before the
E. histolytica cleavage that occurred between the two Thr in
RT2TG. In this case it was shown that the E. histolytica was
able to dissolve the colon mucus because it disrupted the cova-
lent structure necessary for an intactMUC2 polymer. Thus, the
RgpB will potentially also dissolve the MUC2 mucus gel because
the cleavage is at the same location. It is interesting that only two
cleavage sites are used by two different pathogenic organisms for
degrading MUC2. The cleavage shared area around the IRTT
sequence,whichcausesdisruptionof theMUC2polymer, suggests
that this region is a weak point in the human MUC2 mucin, a
sequence that is absent in themouseMuc2 (15).
The IR2TT cleavage site contains two Thr that could be
O-glycosylated. Testing recombinant GalNAc-Ts on a syn-
thetic peptide revealed that GalNAc-T3 added GalNAc to the
second Thr in the IRTT sequence and that this glycosylation
inhibited the cleavage by RgpB. None of the other GalNAc-Ts
found in the colonic epitheliumwas able to glycosylate this site.
However, combining GalNAc-T3 with GalNAc-T7 further gly-
cosylated the IRTT-containing peptide and rendered it com-
pletely resistant to cleavage by RgpB. No other GalNAc-Ts,
single or in combination with the glycopeptide specific
GalNAc-transferases, affected the IRTT site, and the obtained
glycopeptides remained susceptible to RgpB cleavage. When
MUC2-C was expressed in CHO cells, it was susceptible to
RgpB digestion and only after introduction of GalNAc-T3
MUC2-C became resistant to cleavage by RgpB, confirming the
role of GalNAc-T3 in glycosylation of MUC2-C and its protec-
tion from proteolysis ex vivo. The repertoire of GalNAc-Ts
endogenously expressed inCHO-K1 includesGalNAc-T2, -T7,
-T11, and -T20 (35), and coexpression of GalNAc-T3 with the
endogenous GalNAc-T7 should in accordance with the in vitro
glycosylation generate a fully resistant MUC2 mucin as
observed for the synthetic peptide.
We identified protein expression of GalNAc-T1, -T2, -T3,
-T4, -T5, -T7, and -T12 in the colonic epithelial cells.We could
also show that the critical GalNAc-T3 is colocalized with
MUC2 in the goblet cells, suggesting that the IRTT sequence of
MUC2 is glycosylated in vivo. GalNAc-T3 deficiency is a rare
congenital condition resulting in the disease familial tumoral
calcinosis characterized by hyperphosphatemia and ectopic
ossifications and caused by a lack of GalNAc-T3-mediated site-
specific O-glycosylation of FGF23 that protects it from inacti-
vating proprotein convertase processing (12, 13). These
patients have not been reported to have any gastrointestinal
symptoms. However, thismay have been overlooked because of
the severe nature of the disease. The in vivo functions of indi-
vidual GalNAc-Ts and their contribution to the O-glycopro-
teome is largely unexplored, as are the final biological conse-
quences of changes in the O-glycoproteome as an effect of
changes in expression of GalNAc-Ts.We are beginning to gain
insights into theO-glycoproteome of a single GalNAc-T, and it
has been demonstrated to give qualitative changes in theO-gly-
coproteome (38). Given that GalNAc-T3 seems to be ubiqui-
tously expressed in human colon, onewould envision that path-
ogenic bacterial enzymes of the type described here would not
be able to degrade the MUC2 mucus layer under normal con-
ditions and have gross effects. However, because O-glycosyla-
tion site occupancy often varies or is incomplete, this may
render subjects more susceptible to mucus degradation by
pathogens such as P. gingivalis and E. histolytica Earlier work
by our group has shown that E. histolytica secreted proteases
are capable of degrading MUC2 produced by LS 174T cells, a
cell line that endogenously express GalNAc-T3 (39). Because
theMUC2mucin produced in this cell line was dissolved by the
E. histolytica secretion, it emphasizes that the glycosylation is
often incomplete. It can thus be suggested that also humans,
which normally have GalNAc-T3 in their goblet cells, will be
variably susceptible toMUC2 cleavage by the E. histolytica and
P. gingivalis proteases. The observation that glycosylation at a
single amino acid is important for protecting the protein core of
MUC2 from degradation supports the idea that especially
O-glycosylation is important for intestinal protection. Recently,
we demonstrated that deletion of a single glycosyltransferase
that extends theO-glycans on the C3 of the GalNAc, the Core 1
enzyme, caused spontaneous colitis (40). This finding indicates
that glycosylation of proteins, especially the mucins, is very
important for its protective properties and has developed in an
evolutionary balance between the host and commensal and
pathogenic bacteria. P. gingivalis is a well known pathogen that
FIGURE 8. Schematic model of MUC2 polymer degradation by the protease RgpB. A, the MUC2 mucin forms a dense polymeric network upon secretion by
the goblets cells in colon (1, 3). B, the MUC2 mucin polymer forms highly organized ring-like structures held together by disulfide linkage at the MUC2 N- and
C-terminal regions. C, the central part of MUC2 consists of two mucin domains that are protected from proteolytic cleavage by its high glycosylation. Disruption
of the mucus polymer at the termini is prevented by internal disulfide bonds. The position of the cleavage site Arg4320 identified in this study is found in
between these two regions and would result in complete disruption of the mucus gel.
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causes periodontitis (41). P. gingivalis is an anaerobic bacte-
rium and is expected to also thrive in the colon. Although this
has not been studied in detail, recentmetagenomic studies con-
firmed that the Porphyromonadaceae family and P. gingivalis
are represented among the colon microbiota (28, 37). That
P. gingivalis secretes a protease able to cleave MUC2 at a spe-
cific site where it will disrupt the MUC2 polymeric network
suggests that it can also degrade the inner mucus layer in colon
when not fully glycosylated (Fig. 8). The function of this layer is
to separate the intestinal microbiota from the epithelial cells,
such a bacterium would probably increase the number of bac-
teria that can reach the epithelium. As we know that increased
contact with intestinal bacteria, as exemplified by the mouse
lacking the Muc2 mucin (1), causes severe inflammation, it is
not impossible that P. gingivalis may be one of several factors
that could contribute to colitis.
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